Anti-Human PD-1 Reference Antibody (Cetrelimab, RUO) (HS870046)

Name: Anti-Human PD-1 Reference Antibody (Cetrelimab, RUO)
Brand: abinScience
SKU: HS870046
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HS870046
Descripción	Cetrelimab (HS870046) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG4-kappa
Objetivo	CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q15116
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	JNJ-63723283, 2050478-92-5
Fondo	Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo). 1. Fife, BT. et al. (2011) Annals of the New York Academy of Sciences 1217, 45-59. PMID: 21276005 2. Bardhan, K. et al. (2019) Scientific reports 9, 17252. PMID: 31754127 3. Patsoukis, N. et al. (2020) Communications biology 3, 128. PMID: 32184441 4. Xiao, X. et al. (2023) Nature communications 14, 2859. PMID: 37208329 5. Zak, KM. et al. (2015) Structure (London, England : 1993) 23, 2341-2348. PMID: 26602187
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207) Human IgG4 (S228P) Recombinant Isotype Control Antibody (HyHEL-10) (HP298307) Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107)